Strategy Consulting

Bringing a health care technology to the international market is a challenging process that meets with many international, national and local regulations for registration and reimbursement. Pharmerit's team members have extensive experience with market access and policy research and are familiar with research design, surveys, statistical analysis, strategic planning, and reporting in various disease areas.

Market access research

Pharmerit is engaged in a large number of studies which aim to support the development and commercialisation of new products in the US and Europe. These type of studies generally aim at:

• Optimising the penetration of new products in the markets of interest by securing supportive recommendations and guidelines.
• Ensure strong support of the new technology by payers and clinicians.
• Develop market shaping communication strategies aligned with public health and policy makers’ priorities.

Policy research

For governmental bodies we have compared international pricing and reimbursement systems in order to advice these institutions on how to reorganise their system. In this type of research we generally combine literature research with in-depth interview with local experts. Our track record includes:

• A project with a special focus on the manner in which innovative products, me-too products and generics were treated in a number of countries, and what type of health economic evidence was required.
• A project in which we reviewed the scope of the basic healthcare insurance packages by looking at the reimbursement status of multiple medical interventions (tracers) including dental services.

Environmental scan

In our market acces studies we take many aspects into account that are relevant for the new product, such as the clinical environment, disease burden, unmet need in the current health care, and the health economic environment in which the product will be launched.

The latter assessment provides the context within which messages about the new product’s role can be developed, and should ideally identify:

• The current and anticipated major target audiences and decision makers (physicians, health care providers, regulators, or patients and their families).
• The economic incentives under which these target audiences operate, and the processes in place for their review and consideration of health economic data.
• The treatment context within which the product will be placed and the range of alternative treatment strategies against which it will be compared.
• The costs associated with these treatment strategies.

Target product profile

We evaluate the target product profile including assessments of efficacy, safety, effects on quality-of-life and patient reported outcomes, price of the product, mechanism of action, model of administration, dosing, (contra)indications, etcetera. We compare the target product profile with the profile of (potential) competitors.

Interviews

Our strategic studies often include interviews with stakeholders such as payers, policy makers, physicians and patient organisations. The core interview guides include structured qualitative and semi-quantitative questions for high priority topics. Moreover, the value of the target product profile to payers will be evaluated to identify which attributes are required to achieve success.

Countries

We are familiar with the healthcare system and financial structures in many European countries. In the US we work together with Tag and Associates (www.taghealthcare.com).

International network

Pharmerit has extensive experience in conducting strategic surveys in the global market and we have an international network of key opinion leaders and key decision makers in the clinical and reimbursement field respectively.